New Insights into the Association between Metabolic Syndrome Components and the Development of Atherosclerosis
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".
Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 205
Special Issue Editor
2. Cardiovascular Research Group, Hospital Sant Joan de Reus, Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
3. Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
Interests: metabolism; cardiovascular disease; inflammation; extracellular vesicles; omics; epigenetics; precision medicine; biomarker discovery; bioinformatics; biomedical data analysis
Special Issue Information
Dear Colleagues,
Metabolic syndrome (MetS) defines a cluster of interrelated cardiovascular risk factors including obesity, hyperglycemia, hypertension, dyslipidemia, insulin resistance, and central adiposity, linked to chronic inflammation, that severely increases the risk of cardiovascular diseases (CVD). The increasing prevalence of MetS involved the parallel increase of atherosclerosis, a chronic inflammatory metabolic disease caused by the aberrant accumulation of lipids and the infiltration of inflammatory cells at the vascular endothelium. Atherosclerosis is the major underlying cause of CVD, the leading cause of death globally.
Clinical and experimental evidence has demonstrated a close link between MetS and the risk of developing atherosclerosis, whereas the underlying mechanisms remain to be elucidated. In terms of the relationship between MetS and atherosclerosis, obesity and its metabolic disarrangements, including lipid and lipoprotein metabolism, inflammation, oxidative stress, and microbiota have been the most studied topics. Furthermore, the complex crosstalk among metabolic organs and tissues suggests the importance that the intracellular and intercellular communication may play in the pathogenic process of the disease.
In this Special Issue, original research and reviews of the literature evaluating the cellular and molecular aspects linking MetS components with the development of atherosclerosis are encouraged. Submissions with an emphasis on emerging approaches including omics are welcome.
Dr. Neus Martínez-Micaelo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metabolic syndrome
- atherosclerosis
- cardiovascular disease
- endothelial dysfunction
- inflammation
- oxidative stress
- microbiota
- extracellular vesicles
- omics
